Drugs / Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02100436 | Jun 2014 → Mar 2015 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02100436 ↗ |
| Known as | H3N2v MIV | “A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs.” NCT02100436 ↗ |
| Modality | Vaccine | “unadjuvanted subvirion monovalent inactivated split influenza virus vaccine” NCT02100436 ↗ |
| Route | Intramuscular | “administered intramuscularly as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose” NCT02100436 ↗ |